hx-etoposide 400mg/20ml
sandoz sa (pty) ltd - etoposide - solution for infusion - each 20ml solution contains etoposide 400.0 mg
hx-etoposide 50mg/2.5ml
sandoz sa (pty) ltd - etoposide - solution for infusion - each 2.5ml solution contains etoposide 50.0 mg
hx-etoposide 200mg/10ml
sandoz sa (pty) ltd - etoposide - solution for infusion - each 10ml solution contains etoposide 200.0 mg
etoposide injection liquid
fresenius kabi canada ltd - etoposide - liquid - 20mg - etoposide 20mg - antineoplastic agents
etoposide injection liquid
teva canada limited - etoposide - liquid - 20mg - etoposide 20mg - antineoplastic agents
etoposide injection, usp solution
strides pharma canada inc - etoposide - solution - 20mg - etoposide 20mg - antineoplastic agents
pfizer (australia) etoposide 20mg/ml injection vial multidose
pfizer australia pty ltd - etoposide, quantity: 20 mg/ml - injection, concentrated - excipient ingredients: macrogol 300; citric acid; polysorbate 80; ethanol absolute - indications as at 3 april 1996: etoposide injection is indicated for the following: small cell carcinoma of the lung. acute monocytic and myelomonocytic leukaemia. hodgkin's disease. non-hodgkin's lymphoma
etoposide
sandoz pty ltd - etoposide -
toposar etoposide injection solution concentrate
teva parenteral medicines, inc. - etoposide (unii: 6plq3cp4p3) (etoposide - unii:6plq3cp4p3) - etoposide 20 mg in 1 ml
etopophos etoposide 1g (as phosphate) powder for injection vial
link medical products pty ltd t/a link pharmaceuticals - etoposide phosphate, quantity: 1136 mg (equivalent: etoposide, qty 1000 mg) - injection, powder for - excipient ingredients: sodium citrate dihydrate; dextran 40 - indications: for use in the treatment of: *small cell carcinoma of the lung *acute monocytic and myelomonocytic leukaemia *hodgkin's disease *non-hodgkin's lymphoma *testicular tumours.